Treatment of acute Charcot foot with bisphosphonates: A systematic review of the literature

Diabetologia

Volumn 55, Issue 5, 2012, Pages 1258-1264

  Richard, J L ^a   Almasri, M ^b   Schuldiner, S ^a  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b LAPEYRONIE HOSPITAL   (France)

Author keywords

Bisphosphonates; Charcot neuroosteoarthropathy; Diabetic foot; Diabetic neuropathy; Osteoprotegerin; RANK L; Systematic review

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ZOLEDRONIC ACID;

ACUTE CHARCOT NEUROPATHIC OSTEOARTHROPATHY; ANTIINFLAMMATORY ACTIVITY; BONE TURNOVER; CAST APPLICATION; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; IMMOBILIZATION; MONOTHERAPY; MYALGIA; OSTEOARTHROPATHY; PRIORITY JOURNAL; REVIEW; SKIN TEMPERATURE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WALKING AID;

ACUTE DISEASE; ARTHROPATHY, NEUROGENIC; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; HUMANS;

EID: 84862582930     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2507-3     Document Type: Review

References (35)

1. Stanley JC, Collier AM (2008) Charcot osteo-arthropathy. Curr Orthop 22:428-433
2. Sanders LJ, Frykberg RG (2007) The Charcot foot (Pied de Charcot). In: Bowker JH, Pfeifer MA (eds) Levin and O'Neal's the diabetic foot. Mosby Elsevier, Philadelphia, pp 257-283
3. Wukich DK, Sung W (2009) Charcot arthropathy of the foot and ankle: modern concepts and management review. J Diabetes Complications 23:409-426
4. van Baal J, Hubbard R, Game F, Jeffcoate W (2010) Mortality associated with acute Charcot foot and neuropathic foot ulceration. Diabetes Care 33:1086-1089
5. Rajbhandari RC, Jenkins CD, Tesfaye S (2002) Charcot neuroarthropathy in diabetes mellitus. Diabetologia 45:1085-1096
6. Rogers LC, Frykberg RG, Armstrong DG et al (2011) The Charcot foot in diabetes. Diabetes Care 34:2123-2129
7. Jeffcoate WJ, Game F, Cavanagh PR (2005) The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 366:2058-2061
8. Jeffcoate WJ (2008) Charcot neuro-osteoarthropathy. Diabetes Metab Res Rev 24:62-65
9. Molines L, Darmon P, Raccah D (2010) Charcot's foot: newest findings on its pathophysiology, diagnosis and treatment. Diabetes Metab 36:251-255
10. Gough A, Abraha H, Li F et al (1997) Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic Charcot neuroarthropathy. Diabet Med 7:527-531
11. Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A (2008) Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-κB ligand. Diabetologia 51:1035-1040
12. Selby PL, Young MJ, Boulton AJ (1994) Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy? Diabet Med 11:28-31
13. Lyn TA, Greenstein A, Jarrett S, McGonagle D (2005) Acute neuropathic joint disease. A medical emergency? Diabetes Care 28:2962-2964
14. Stansberry KB, Moss QE, Peppard HR, McNitt PM, Vinik AI (1999) Intravenous bisphosphonate rapidly reverses the paradoxical increase in blood flow to the foot in Charcot neuroarthropathy. Diabetes 48:A92
15. Guis S, Pellissier JF, Arniaud D et al (1999) Healing of Charcot's joint by pamidronate infusion. J Rheumatol 26:1843-1845
16. Young MT (1999) The management of neurogenic arthropathy: a tale of two Charcots. Diabetes Metab Res Rev 15:59-64
17. Pakarinen T-K, Laine H-J, Honkonnen SE, Peltonen J, Oksala H, Lahtela J (2002) Charcot arthropathy of diabetic foot: current concepts and review of 36 cases. Scand J Surg 9:195-201
18. MorenoM, Gratacós J, Casado E, Galisteo C, Orellana C, LarrosaM (2007) Utilidad del pamidronato en el tratamiento de la artropatía de Charcot (Usefulness of pamidronate in the treatment of Charcot's arthropathy). Reumatol Clin 3:257-261, article in Spanish
19. Naqvi A, Cuchacovich R, Saketkoo L, Espinoza LR (2008) Acute Charcot arthropathy successfully treated with Pamidronate: longterm follow-up. Am J Med Sci 335:145-148
20. Anderson JJ, Woelffer KE, Holtzman JJ, Jacobs AM (2004) Bisphophonates for the treatment of Charcot neuroarthropathy. J Foot Ankle Surg 43:2285-2289
21. Jude EB, Selby PL, Burgess J, Lilleystone P, Mawer EB et al (2001) Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 44:2032-2037
22. Pitocco D, Ruotolo V, Caputo S et al (2005) Six-month treatment with Alendronate in acute Charcot neuroarthropathy. Diabetes Care 28:1214-1215
23. Pakarinen T-K, Laine H-J, Mäenpää H, Mattila P, Lahtela J (2011) The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy. A pilot randomized controlled trial. Diabetes Care 34:1514-1516
24. Vega D, Maalouf NM, Sakhaee K (2007) The role of receptor activator of nuclear factor-κB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 92:4514-4521
25. Uccioli L, Sinistro A, Almerighi C et al (2010) Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot. Diabetes Care 33:350-355
26. Pitocco D, Zelano G, Gioffré G et al (2009) Association between osteoprotegerin G1181C and T245G polymorphisms and diabetic Charcot neuroarthropathy. A case-control study. Diabetes Care 32:1694-1697
27. Korzon-Burakowska A, Jakóbkiewicz-Banecka J, Fiedosiuk A et al (2011) Osteoprotegerin gene polymorphism in diabetic Charcot neuroarthropathy. Diabet Med. doi:10.1111/j.1464-5491.2011.03442.x
28. PinzurMS, Lio T, PosnerM(2006) Treatment of Eichenholtz stage 1 Charcot foot arthropathy with a weightbearing total contact cast. Foot Ankle Int 27:324-329
29. Frith JC,Mönkkönen J, Auriola S,Mönkkönen H, RogersMJ (2001) The molecular mechanism of action of the antiresorptive and anti-inflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44:2201-2210
30. Russell RGG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733-759
31. Maksymowych WP (2002) Bisphosphonates-anti-inflammatory properties. Curr Med Chem Anti Inflamm Anti Allergy Agents 1:15-28
32. Smith C, Kumar S, Causby R (2007) The effectiveness of nonsurgical interventions in the treatment of Charcot foot. Int J Evid Based Healthc 5:437-449
33. Game FL, Catlow R, Jones GR, Edmonds ME, Jude EB, Rayman G, Jeffcoate WJ (2012) Audit of acute Charcot's disease in the UK: the CDUK study. Diabetologia 55:32-35
34. DrakeMT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032-1045
35. Bem R, Jirkovská A, Fejfarová V, Skibová J, Jude EB (2006) Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy. A randomized clinical trial. Diabetes Care 29:1392-1394